|
1
|
Crissien AM and Frenette C: Current
management of hepatocellular carcinoma. Gastroenterol Hepatol (N
Y). 10:153–161. 2014.PubMed/NCBI
|
|
2
|
Altekruse SF, McGlynn KA and Reichman ME:
Hepatocellular carcinoma incidence, mortality, and survival trends
in the united states from 1975 to 2005. J Clin Oncol. 27:1485–1491.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hoshida Y, Fuchs BC and Tanabe KK:
Prevention of hepatocellular carcinoma: Potential targets,
experimental models, and clinical challenges. Curr Can Drug
Targets. 12:1129–1159. 2012. View Article : Google Scholar
|
|
4
|
Cervello M, McCubrey JA, Cusimano A,
Lampiasi N, Azzolina A and Montalto G: Targeted therapy for
hepatocellular carcinoma: Novel agents on the horizon. Oncotarget.
3:236–260. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Boguski MS, Mandl KD and Sukhatme VP: Drug
discovery. Repurposing with a difference. Science. 324:1394–1395.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Knapp S: New opportunities for kinase drug
repurposing and target discovery. Br J Cancer. 118:936–937. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chen JJ, Cai N, Chen GZ, Jia CC, Qiu DB,
Du C, Liu W, Yang Y, Long ZJ and Zhang Q: The neuroleptic drug
pimozide inhibits stem-like cell maintenance and tumorigenicity in
hepatocellular carcinoma. Oncotarget. 8:17593–17609.
2017.PubMed/NCBI
|
|
8
|
Zhou W, Chen MK, Yu HT, Zhong ZH, Cai N,
Chen GZ, Zhang P and Chen JJ: The antipsychotic drug pimozide
inhibits cell growth in prostate cancer through suppression of
STAT3 activation. Int J Oncol. 48:322–328. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cai N, Zhou W, Ye LL, Chen J, Liang QN,
Chang G and Chen JJ: The STAT3 inhibitor pimozide impedes cell
proliferation and induces ROS generation in human osteosarcoma by
suppressing catalase expression. Am J Transl Res. 9:3853–3866.
2017.PubMed/NCBI
|
|
10
|
Strobl JS, Melkoumian Z, Peterson VA and
Hylton H: The cell death response to gamma-radiation in MCF-7 cells
is enhanced by a neuroleptic drug, pimozide. Breast Cancer Res
Treat. 51:83–95. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jia H, Ren W, Feng Y, Wei T, Guo M, Guo J,
Zhao J, Song X, Wang M, Zhao T, et al: The enhanced antitumour
response of pimozide combined with the IDO inhibitor L-MT in
melanoma. Int J Oncol. 53:949–960. 2018.PubMed/NCBI
|
|
12
|
Fako V, Yu Z, Henrich CJ, Ransom T, Budhu
AS and Wang XW: Inhibition of wnt/β-catenin signaling in
hepatocellular carcinoma by an antipsychotic drug pimozide. Int J
Biol Sci. 12:768–775. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ren Y, Tao J, Jiang Z, Guo D and Tang J:
Pimozide suppresses colorectal cancer via inhibition of
Wnt/β-catenin signaling pathway. Life Sci. 209:267–273. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gonçalves JM, Silva CAB, Rivero ERC and
Cordeiro MMR: Inhibition of cancer stem cells promoted by Pimozide.
Clin Exp Pharmacol Physiol. 46:116–125. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yan D, Parker RE, Wang X, Frye SV, Earp HS
III, DeRyckere D and Graham DK: MERTK promotes resistance to
irreversible EGFR tyrosine kinase inhibitors in non-small cell lung
cancers expressing wild-type EGFR family members. Clin Can Res.
24:6523–6535. 2018. View Article : Google Scholar
|
|
16
|
Abdallah SM and Hirsh V: Irreversible
tyrosine kinase inhibition of epidermal growth factor receptor with
afatinib in EGFR activating mutation-positive advanced
non-small-cell lung cancer. Curr Oncol. 25 (Suppl 1):S9–S17. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sagot I and Laporte D: Quiescence, an
individual journey. Curr Genet. 65:695–699. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Heldt FS, Barr AR, Cooper S, Bakal C and
Novák B: A comprehensive model for the proliferation-quiescence
decision in response to endogenous DNA damage in human cells. Proc
Natl Acad Sci USA. 115:2532–2537. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cai N, Xie SJ, Qiu DB, Jia CC, Du C, Liu
W, Chen JJ and Zhang Q: Potential effects of α-mangostin in the
prevention and treatment of hepatocellular carcinoma. J Funct
Foods. 26:309–318. 2016. View Article : Google Scholar
|
|
20
|
Agarwal SM, Pal D, Gupta M and Saini R:
Insight into discovery of next generation reversible TMLR
inhibitors targeting EGFR activating and drug resistant T790M
mutants. Curr Can Drug Targets. 17:617–636. 2017.
|
|
21
|
Rybczynska M, Spitaler M, Knebel NG, Boeck
G, Grunicke H and Hofmann J: Effects of miltefosine on various
biochemical parameters in a panel of tumor cell lines with
different sensitivities. Biochem Pharmacol. 62:765–772. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Dakir EH, Pickard A, Srivastava K,
McCrudden CM, Gross SR, Lloyd S, Zhang SD, Margariti A, Morgan R,
Rudl PS and El-Tanani M: The anti-psychotic drug pimozide is a
novel chemotherapeutic for breast cancer. Oncotarget.
9:34889–34910. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Strobl JS, Kirkwood KL, Lantz TK, Lewine
MA, Peterson VA and Worley JF III: Inhibition of human breast
cancer cell proliferation in tissue culture by the neuroleptic
agents pimozide and thioridazine. Cancer Res. 50:5399–5405.
1990.PubMed/NCBI
|
|
24
|
Coller HA, Sang L and Roberts JM: A new
description of cellular quiescence. PLoS Biol. 4:e832006.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Aguirre-Ghiso JA: Models, mechanisms and
clinical evidence for cancer dormancy. Nat Rev Cancer. 7:834–846.
2007. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
Alarcón T and Jensen HJ: Quiescence: A
mechanism for escaping the effects of drug on cell populations. J R
Soc Interface. 8:99–106. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Fiore APZP, Ribeiro PF and Bruni-Cardoso
A: Sleeping beauty and the microenvironment enchantment:
Microenvironmental regulation of the proliferation-quiescence
decision in normal tissues and in cancer development. Front Cell
Dev Biol. 6:592018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Recasens A and Munoz L: Targeting cancer
cell dormancy. Trends Pharmacol Sci. 40:30229–30233. 2019.
View Article : Google Scholar
|
|
29
|
Nelson EA, Walker SR, Xiang M, Weisberg E,
Bar-Natan M, Barrett R, Liu S, Kharbanda S, Christie AL, Nicolais
M, et al: The STAT5 inhibitor pimozide displays efficacy in models
of acute myelogenous leukemia driven by FLT3 mutations. Genes
Cancer. 3:503–511. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wishart DS, Feunang YD, Guo AC, Lo EJ,
Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, et al:
DrugBank 5.0: A major update to the DrugBank database for 2018.
Nucleic Acids Res. 46(D1): D1074–D1082. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Bhattarai D, Singh S, Jang Y, Hyeon Han S,
Lee K and Choi Y: An insight into drug repositioning for the
development of novel anti-cancer drugs. Curr Top Med Chem.
16:2156–2168. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Samuel SM, Varghese E, Varghese S and
Büsselberg D: Challenges and perspectives in the treatment of
diabetes associated breast cancer. Cancer Treat Rev. 70:98–111.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
El-Arabey AA: Correction to: New insight
for metformin against bladder cancer. Genes Environ. 40:162018.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Forner A, Reig M and Bruix J:
Hepatocellular carcinoma. Lancet. 391:1301–1314. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Jiang C, Xu R, Li XX, Zhou YF, Xu XY, Yang
Y, Wang HY and Zheng XFS: Sorafenib and carfilzomib synergistically
inhibit the proliferation, survival, and metastasis of
hepatocellular carcinoma. Mol Cancer Ther. 17:2610–2621. 2018.
View Article : Google Scholar : PubMed/NCBI
|
